Longvida®
Research
Longvida®
Research
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Curcumin decreases cytokine levels involved in mucositis in autologous transplant setting: A pharmacokinetic-pharmacodynamic study.
Khattry N et al.
Poster presented at 54thAmerican Society of Hematology (ASH) Annul Meeting. Atlanta, GA. 2012 Dec 08. Blood. 120(21): 3039.
The absorption and efficacy of Longvida in lozenge form in a common oral inflammatory and fibrotic condition was tested compared to the standard of care (clobetasol steroid ointment). Subjects taking Longvida observed improvements in endpoints significantly better than those receiving steroid treatment; and therapeutic plasma levels were detected through buccal absorption.
Diverse effects of a low-dose supplement of lipidated curcumin [as Longvida®] in healthy middle-aged people.
DiSilvestro et al.
The Ohio State University. Nutr. J. 2012 Sep 26. 11(79). doi: 10.1186/1475-2891-11-79
This study is believed to be the first curcumin trial in healthy people to show improvement in a number of key biomarkers related to healthy aging. Randomized, placebo-controlled study in 39 subjects showing excellent safety as well as significant improvements in markers supporting cognitive health, cardiovascular health, and anti-aging versus placebo.
Acute human pharmacokinetics of a lipid-dissolved turmeric extract.
Shah et al.
Planta Med. 2012. 48-PH5.
This study concluded that a dose as low as 200mg of Longvida reaches blood levels of free curcumin required for healthy brain aging. Analyzed blood samples with and without the use of glucuronidase enzyme, finding very little of the glucuronidated form compared to previous studies on curcumin.
Chronic dosing safety assessment of a solid lipid curcumin particle [Longvida®] formulation.
Dadhaniya et al.
Food Chem Toxicol. 2011 Aug. 49(8): 1834-42.
This study is one of the few published long-term dosing trials looking at the safety of enhanced forms of curcumin. As one part of the Longvida GRAS determination by an independent panel of scientific experts, this study found that Longvida dosing at ~100x the human equivalent dose for 90-days led to no abnormalities or safety issues.
Improved expression of glial-fibrillar acid protein (GFAP) in transgenic mice after dosing of curcumin (Longvida®).
National University of Singapore, 2011. Unpublished.
Early data from this ongoing study funded by the Singapore government showed improvement in the brain cell health marker, glial-fibrillar acidic protein (GFAP), after 1 week of feeding Longvida in p25 mice, which are bred to exhibit chronic neuroinflammation and tau abnormalities. GFAP is the key marker for gliosis occurring as a result of brain damage, head trauma, inflammation, and neurodegeneration.
Late stage intervention with curcumin (Longvida®) reduces soluble tau oligomers.
Sally Frautschy Ph.D. AAIC. 2011. Paris, France. Oral presentation.
In a talk attended by hundreds of expert neuroscientists and Alzheimer’s researchers, UCLA presented data showing low-dose Longvida fed to mice with tau tangles led to improvements in memory, mood, synaptic markers, AMPA glutamate receptors, heat shock protein, and harmful tau oligomers.
Safety and pharmacokinetics of a solid lipid curcumin particle formulation in patients and healthy volunteers.
Gota et al.
Tata Memorial Cancer Centre. J Ag Food Chem. 2010. 58(4): 2095-2099.
Human bioavailability study demonstrating significantly greater plasma levels of free (unconjugated) curcumin after a single dose of Longvida in both healthy and disease states with 65x greater Cmax and >100x greater AUC than 95% curcuminoids.
Efficacy of curcumin formulations in relation to systemic availability in the brain and different blood compartments in neuroinflammatory and AD models.
Frautschy SA et al.
39th Annual Meeting of the Society of Neuroscience. Chicago, IL. 2009 Oct. Poster Presentation.
Based on NIH funding, UCLA neuroscientists found that Longvida exhibited the best absorption after comparing different formulations including the use of lipids, antioxidants, nanoparticles, and cyclodextrins. Low-dose Longvida prevented the loss of hippocampal synaptoshysin, suggesting a role for Longvida in neurogenesis, the creation of new brain cells. This study established blood compartments other than plasma that are better indicators of tissue levels of free curcumin after Longvida dosing.
Omega 3 DHA and a bioavailable curcumin formulation (Longvida®) synergize.
Frautschy SA et al.
39th Annual Meeting of the Society of Neuroscience. Chicago, IL. 2009 Oct. Poster Presentation.
This study, NIH and VA funded, found a synergy existed when DHA and Longvida were taken in combination. UCLA authors wrote: “While DHA alone is very effective in vitro and with early interventions in vivo, effective late stage cocktail interventions in AD model mice with significant pre-existing pathology, neuron loss, and cognitive deficits are clearly dependent on the inclusion of the bioavailable lipidated curcumin.”
Improving bioavailability of curcumin by solid lipid particle (Longvida®).
Frautschy et al.
UCLA, 38th Annual Meeting of the Society of Neuroscience. Washington DC. 2008 Nov 15. Poster Presentation.
Improvements in plasma amyloid, and brain amyloid clearance were observed in transgenic mice after four days of Longvida dosing. Therapeutic brain levels of free curcumin using established LC/MS/MS methodology were found after 2 weeks of feeding with Longvida, reaching levels required.
Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation.
Begum et al.
Pharmacol Exp Ther. 2008 Jul. 326(1): 196-208.
Key NIH-funded work and the basis of later work with Longvida, this UCLA-Veterans Administration (VA) study showed that Longvida absorbed into brain within 3-hours after the initial dose, and was the first paper to show that Longvida was better absorbed and more effective in models than unformulated curcumin.
Curcumin and yoga exercise effects in veterans at risk.
UCLA, Ongoing
Effectiveness of curcumin in modulating chronic inflammation, oxidative stress, endocrine dysfunction, and joint health of the geriatric horse.
Gluck Equine Research Center, Unpublished Internal Report
Chronic neuroinflammation, progressive neurodegeneration, cognitive decline.
University of Western Sydney, Ongoing.
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Curcumin decreases cytokine levels involved in mucositis in autologous transplant setting: A pharmacokinetic-pharmacodynamic study.
Khattry N et al.
Poster presented at 54thAmerican Society of Hematology (ASH) Annul Meeting. Atlanta, GA. 2012 Dec 08. Blood. 120(21): 3039.
The absorption and efficacy of Longvida in lozenge form in a common oral inflammatory and fibrotic condition was tested compared to the standard of care (clobetasol steroid ointment). Subjects taking Longvida observed improvements in endpoints significantly better than those receiving steroid treatment; and therapeutic plasma levels were detected through buccal absorption.
Diverse effects of a low-dose supplement of lipidated curcumin [as Longvida®] in healthy middle-aged people.
DiSilvestro et al.
The Ohio State University. Nutr. J. 2012 Sep 26. 11(79). doi: 10.1186/1475-2891-11-79
This study is believed to be the first curcumin trial in healthy people to show improvement in a number of key biomarkers related to healthy aging. Randomized, placebo-controlled study in 39 subjects showing excellent safety as well as significant improvements in markers supporting cognitive health, cardiovascular health, and anti-aging versus placebo.
Acute human pharmacokinetics of a lipid-dissolved turmeric extract.
Shah et al.
Planta Med. 2012. 48-PH5.
This study concluded that a dose as low as 200mg of Longvida reaches blood levels of free curcumin required for healthy brain aging. Analyzed blood samples with and without the use of glucuronidase enzyme, finding very little of the glucuronidated form compared to previous studies on curcumin.
Chronic dosing safety assessment of a solid lipid curcumin particle [Longvida®] formulation.
Dadhaniya et al.
Food Chem Toxicol. 2011 Aug. 49(8): 1834-42.
This study is one of the few published long-term dosing trials looking at the safety of enhanced forms of curcumin. As one part of the Longvida GRAS determination by an independent panel of scientific experts, this study found that Longvida dosing at ~100x the human equivalent dose for 90-days led to no abnormalities or safety issues.
Improved expression of glial-fibrillar acid protein (GFAP) in transgenic mice after dosing of curcumin (Longvida®).
National University of Singapore, 2011. Unpublished.
Early data from this ongoing study funded by the Singapore government showed improvement in the brain cell health marker, glial-fibrillar acidic protein (GFAP), after 1 week of feeding Longvida in p25 mice, which are bred to exhibit chronic neuroinflammation and tau abnormalities. GFAP is the key marker for gliosis occurring as a result of brain damage, head trauma, inflammation, and neurodegeneration.
Late stage intervention with curcumin (Longvida®) reduces soluble tau oligomers.
Sally Frautschy Ph.D. AAIC. 2011. Paris, France. Oral presentation.
In a talk attended by hundreds of expert neuroscientists and Alzheimer’s researchers, UCLA presented data showing low-dose Longvida fed to mice with tau tangles led to improvements in memory, mood, synaptic markers, AMPA glutamate receptors, heat shock protein, and harmful tau oligomers.
Safety and pharmacokinetics of a solid lipid curcumin particle formulation in patients and healthy volunteers.
Gota et al.
Tata Memorial Cancer Centre. J Ag Food Chem. 2010. 58(4): 2095-2099.
Human bioavailability study demonstrating significantly greater plasma levels of free (unconjugated) curcumin after a single dose of Longvida in both healthy and disease states with 65x greater Cmax and >100x greater AUC than 95% curcuminoids.
Efficacy of curcumin formulations in relation to systemic availability in the brain and different blood compartments in neuroinflammatory and AD models.
Frautschy SA et al.
39th Annual Meeting of the Society of Neuroscience. Chicago, IL. 2009 Oct. Poster Presentation.
Based on NIH funding, UCLA neuroscientists found that Longvida exhibited the best absorption after comparing different formulations including the use of lipids, antioxidants, nanoparticles, and cyclodextrins. Low-dose Longvida prevented the loss of hippocampal synaptoshysin, suggesting a role for Longvida in neurogenesis, the creation of new brain cells. This study established blood compartments other than plasma that are better indicators of tissue levels of free curcumin after Longvida dosing.
Omega 3 DHA and a bioavailable curcumin formulation (Longvida®) synergize.
Frautschy SA et al.
39th Annual Meeting of the Society of Neuroscience. Chicago, IL. 2009 Oct. Poster Presentation.
This study, NIH and VA funded, found a synergy existed when DHA and Longvida were taken in combination. UCLA authors wrote: “While DHA alone is very effective in vitro and with early interventions in vivo, effective late stage cocktail interventions in AD model mice with significant pre-existing pathology, neuron loss, and cognitive deficits are clearly dependent on the inclusion of the bioavailable lipidated curcumin.”
Improving bioavailability of curcumin by solid lipid particle (Longvida®).
Frautschy et al.
UCLA, 38th Annual Meeting of the Society of Neuroscience. Washington DC. 2008 Nov 15. Poster Presentation.
Improvements in plasma amyloid, and brain amyloid clearance were observed in transgenic mice after four days of Longvida dosing. Therapeutic brain levels of free curcumin using established LC/MS/MS methodology were found after 2 weeks of feeding with Longvida, reaching levels required.
Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation.
Begum et al.
Pharmacol Exp Ther. 2008 Jul. 326(1): 196-208.
Key NIH-funded work and the basis of later work with Longvida, this UCLA-Veterans Administration (VA) study showed that Longvida absorbed into brain within 3-hours after the initial dose, and was the first paper to show that Longvida was better absorbed and more effective in models than unformulated curcumin.
Curcumin and yoga exercise effects in veterans at risk.
UCLA, Ongoing
Effectiveness of curcumin in modulating chronic inflammation, oxidative stress, endocrine dysfunction, and joint health of the geriatric horse.
Gluck Equine Research Center, Unpublished Internal Report
Chronic neuroinflammation, progressive neurodegeneration, cognitive decline.
University of Western Sydney, Ongoing.
